Reaction: Ivacaftor to 1 product

Reaction
Ivacaftor
DB08820
M1 (hydroxymethyl-ivacaftor)
DBMET02318
Reaction type
Not Available
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
active
References
  1. Schneider EK, Reyes-Ortega F, Li J, Velkov T: Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients. J Vis Exp. 2017 Oct 15;(128). doi: 10.3791/56084. [Article]
  2. Fohner AE, McDonagh EM, Clancy JP, Whirl Carrillo M, Altman RB, Klein TE: PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017 Jan;27(1):39-42. doi: 10.1097/FPC.0000000000000246. [Article]
  3. FDA Approved Drug Products: Kalydeco (ivacaftor) tablets or granules, for oral use [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cytochrome P450 3A4Not AvailableNot Availableimplied
Cytochrome P450 3A5Not AvailableNot Availableimplied